Bardin Hill Management Partners’s Blueprint Medicines BPMC Stock Holding History

Bardin Hill Management Partners’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,210	Closed	-$540K	–	11
2025 Q2	$540K	Buy	+4,210	New	+$437K	0.32%	25

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bardin Hill Management Partners's BPMC Position: Q3 2025 in Review

Bardin Hill Management Partners sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 4,210 shares — an estimated $540K sold.

Bardin Hill Management Partners first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $540K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Bardin Hill Management Partners reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Bardin Hill Management Partners sold 4,210 Blueprint Medicines shares in Q3 2025, an estimated $540K.
Bardin Hill Management Partners first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
Bardin Hill Management Partners's Blueprint Medicines position peaked at $540K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Bardin Hill Management Partners's 13F filing for Q3 2025, filed 12 Nov 2025.